Which medications are covered under the GLP-1 Bridge?

Reported coverage includes Wegovy (injection and tablet forms) and Zepbound (KwikPen), used specifically for weight reduction and maintenance. Coverage details can change as CMS finalizes the program, so confirm the current drug list with CMS or your Part D plan before your appointment.

Does the $50 GLP-1 Bridge copay count toward my Part D deductible or out-of-pocket limit?

No. Because the Bridge operates outside the standard Part D benefit payment flow, the $50 copay does not count toward your Part D deductible or your annual out-of-pocket spending limit.

What happens when the GLP-1 Bridge program ends on December 31, 2027?

The Bridge is explicitly time-limited. Unless CMS extends or replaces it, coverage under the $50 copay structure ends on that date, and any continued GLP-1 coverage would fall back to your Part D plan’s normal formulary, tier, and prior authorization rules — which may mean a much higher cost or no coverage at all. Ask your prescriber and Part D plan about a transition plan well before the end date rather than after.

Does Medicare Cover GLP-1 Medications? The GLP-1 Bridge, Explained

Q: What is the Medicare GLP-1 Bridge program?

The Medicare GLP-1 Bridge is a temporary CMS demonstration that lets eligible Medicare Part D beneficiaries get certain GLP-1 medications for weight management for a $50 monthly copay, running from July 1, 2026 through December 31, 2027. It operates outside the normal Part D benefit — a doctor submits a prior authorization and prescription to a CMS central processor rather than to the beneficiary’s Part D plan directly.

Q: Who is eligible for the Medicare GLP-1 Bridge?

Reported eligibility criteria include a BMI of 30 or higher plus a diagnosis such as heart failure, uncontrolled hypertension, or kidney disease, or a BMI of 27 or higher plus a history of stroke, prediabetes, heart attack, or peripheral artery disease. You must already be enrolled in a Medicare Part D plan. Because eligibility rules can be refined as CMS implements the program, confirm current criteria directly with CMS or your Part D plan before assuming you qualify.

Quick Answer

For years, standard Medicare Part D excluded weight-loss drugs by statute, which meant most Medicare beneficiaries paid full price for GLP-1 medications prescribed for weight management. That changed with the Medicare GLP-1 Bridge, a temporary CMS demonstration running July 1, 2026 through December 31, 2027. Eligible beneficiaries who meet specific BMI-plus-comorbidity criteria can get certain GLP-1 medications for a flat $50 monthly copay. The catch: it's a time-limited program with its own eligibility rules and a separate prior authorization process, not a permanent change to Part D — and the rules are still being finalized as CMS rolls it out, so verify current details before you count on it.

Key Takeaways

✓The Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027 — it is temporary, not a permanent Part D benefit change.
✓You must already be enrolled in Medicare Part D to participate.
✓Reported eligibility ties to BMI plus a qualifying condition (e.g., BMI ≥30 with heart failure, uncontrolled hypertension, or kidney disease; or BMI ≥27 with a history of stroke, prediabetes, heart attack, or peripheral artery disease).
✓The $50 copay is separate from normal Part D cost-sharing — it does not count toward your deductible or annual out-of-pocket limit.
✓Your doctor submits prior authorization and the prescription to a CMS central processor, not to your Part D plan directly — a different workflow than a standard PA.
✓A related CMS initiative, the BALANCE Model, has been delayed indefinitely as of CMS’s May 2026 update — the Bridge is the program actually operating.
✓Because this is new and still being implemented, confirm current eligibility, covered drugs, and paperwork requirements directly with CMS or your Part D plan before your appointment.

Why This Is a Big Deal for Medicare Beneficiaries

Medicare Part D has historically excluded coverage of medications used specifically for weight loss — the statute treats "agents used for weight loss" as a category Part D plans aren't required to cover, regardless of formulary. That's a different rule than the one commercial insurers or employer plans operate under, and it's why many Medicare beneficiaries taking Ozempic for type 2 diabetes had coverage while a nearly identical GLP-1 prescribed for obesity alone did not. The GLP-1 Bridge doesn't rewrite that underlying statute, but it creates a time-limited, separately administered pathway around it — effectively a government-run bridge program, similar in spirit to a manufacturer savings card, except run through CMS rather than a drug manufacturer.

Who Qualifies

Eligibility for the Bridge is not simply "anyone on Medicare who wants weight loss medication." Reported criteria tie BMI to a specific qualifying health condition:

BMI of 30 or higher, plus a diagnosis of heart failure, uncontrolled hypertension, or kidney disease; or
BMI of 27 or higher, plus a history of stroke, prediabetes, a previous heart attack, or peripheral artery disease.

You must also already be enrolled in a Medicare Part D plan — the Bridge is layered on top of Part D enrollment, not a stand-alone benefit. Because this is a new federal demonstration still being operationalized, treat the criteria above as a starting point for a conversation with your prescriber and Part D plan, not a guarantee. CMS has published FAQ material for providers and plans as implementation details firm up, and those specifics should govern over any secondhand summary, including this one.

Which Medications Are Covered

Reported coverage under the Bridge includes Wegovy (both the injection and tablet forms) and Zepbound (KwikPen), specifically when used to reduce excess body weight and maintain weight reduction. This is narrower than "all GLP-1 medications" — a drug prescribed primarily for type 2 diabetes management, rather than weight reduction, generally falls under Part D's standard diabetes-drug coverage rules instead, which is a separate pathway with its own tiers and cost-sharing. If you're not sure which pathway applies to your prescription, ask your Part D plan directly — the distinction affects both your cost and which process your doctor needs to use.

How the Prior Authorization Actually Works

This is the part that surprises people who've been through a standard Part D prior authorization before: the Bridge does not route through your Part D plan's usual PA process. Instead, your prescriber submits a prior authorization request and the prescription directly to a CMS central processor. As part of that submission, your doctor confirms you've received counseling on lifestyle changes appropriate to take alongside a GLP-1 medication. Practically, this means:

Your prescriber's office needs to know the Bridge exists and use the correct submission channel — not every office will be familiar with it yet, especially early in the program.
A prior authorization approved for your Part D plan's standard formulary does not automatically carry over to Bridge eligibility, and vice versa. They are separate approvals for separate coverage pathways.
Ask your prescriber's office directly: "Can you submit a GLP-1 Bridge prior authorization to the CMS central processor, not just a standard Part D PA?" That specific phrasing matters, since the two processes are easy to conflate.

What the $50 Copay Does and Doesn't Cover

Eligible beneficiaries pay $50 for a one-month supply of a covered GLP-1 medication through the Bridge. Because the program runs outside the normal Part D benefit payment flow, that $50 does not count toward your Part D deductible or your annual out-of-pocket spending limit — it's a separate cost bucket, not a discount applied within your existing Part D cost-sharing structure. That also means Bridge spending won't help you reach catastrophic coverage faster the way normal Part D drug spending would. If you're taking other medications through standard Part D coverage, keep those two cost tracks straight when you're budgeting.

How This Differs from a Manufacturer Savings Card

People familiar with manufacturer copay cards sometimes assume the Bridge works the same way. It doesn't: manufacturer savings programs are generally unavailable to Medicare beneficiaries specifically because federal anti-kickback rules restrict manufacturer discounts for government-insured patients. The Bridge is a CMS-run substitute that exists in part because that private-market savings-card route is closed to Medicare enrollees. See our manufacturer savings programs guide for how those cards work for commercially insured patients, and why the same offer usually isn't open to you on Medicare.

Navigating a prior authorization or a coverage change on Medicare? Our insurance guides walk through the process step by step.

See How Prior Authorization Works →

What Happens When the Program Ends

The Bridge has a hard end date: December 31, 2027, unless CMS extends or replaces it before then. That matters for planning purposes in a way that's easy to overlook while you're focused on getting approved today. If you start the Bridge in 2026 or 2027, you're building a medication routine around a $50 copay that is not guaranteed to continue past the program's end date. When your coverage reverts to standard Part D rules, your medication may land on a much higher formulary tier, may require its own separate prior authorization, or may not be covered for weight management at all, depending on how your plan's formulary treats GLP-1 drugs outside the Bridge.

Ask your prescriber's office and your Part D plan, well before the end date rather than after, what your options look like if the Bridge isn't renewed: whether a therapeutic alternative might be covered under standard Part D, whether your diagnosis would separately qualify the drug as a diabetes medication rather than a weight-loss medication, and what manufacturer patient assistance programs (separate from the anti-kickback-restricted copay cards) might apply to Medicare beneficiaries specifically.

A Related Program Was Delayed — Don't Confuse the Two

CMS has also discussed a separate, larger initiative sometimes referred to as the BALANCE Model, aimed at broader GLP-1 affordability. As of CMS's May 2026 update, the Part D portion of that model has been delayed indefinitely. The GLP-1 Bridge is the program that is actually running on the schedule above — don't assume a headline about one program describes the other, and don't assume the Bridge's protections extend beyond what CMS has specifically published for it.

Original Medicare vs. Medicare Advantage: Where the Bridge Sits

How you get your Medicare coverage changes who you should call with questions. If you have Original Medicare with a standalone Part D prescription drug plan, your Part D plan and your prescriber are the two parties involved in a Bridge prior authorization. If you have a Medicare Advantage plan that includes drug coverage (an MA-PD plan), your plan administers both your medical and drug benefits together, but the Bridge's central-processor pathway still applies to the drug side specifically — it doesn't change how your Medicare Advantage plan handles medical services. Either way, the same underlying eligibility criteria and $50 copay structure apply; what differs is which customer service line can actually answer your specific billing question. Have your Medicare card and your plan's member ID ready before you call, and ask directly whether you have a standalone Part D plan or an MA-PD plan if you're not sure — it determines which phone number on the back of your card is the right one.

What to Bring to the Appointment Where You Raise This

Because the Bridge is new, don't assume your prescriber's office has already built it into their workflow. Coming prepared shortens the visit:

Your Medicare card and Part D (or MA-PD) plan member ID.
A list of diagnosed conditions relevant to the eligibility criteria (heart failure, hypertension, kidney disease, stroke history, prediabetes, prior heart attack, or peripheral artery disease), along with which physician diagnosed each one and roughly when.
Your most recent weight and height, or a recent BMI calculation, if your office hasn't already recorded one this visit.
A specific question: "Can your office submit a Medicare GLP-1 Bridge prior authorization to the CMS central processor for me?" — naming the program directly avoids it being processed as a standard Part D request by mistake.

Steps to Take If You Think You Qualify

Confirm you're enrolled in a Medicare Part D plan — the Bridge requires existing Part D enrollment.
Talk to your prescriber about whether your BMI and diagnosed conditions match the reported eligibility criteria above.
Ask your prescriber's office specifically about the GLP-1 Bridge central-processor submission — not a standard Part D prior authorization.
Confirm with your Part D plan or CMS directly which medications and dosing forms are currently covered, since program details can be refined during rollout.
Set a calendar reminder well ahead of December 31, 2027 to revisit your coverage options before the program’s scheduled end.

Frequently Asked Questions

What is the Medicare GLP-1 Bridge program?

A temporary CMS demonstration (July 1, 2026 – December 31, 2027) that lets eligible Part D beneficiaries get certain GLP-1 medications for weight management for a $50 monthly copay, processed through a CMS central processor rather than your Part D plan's standard PA workflow.

Who is eligible?

Reported criteria: BMI ≥30 plus heart failure, uncontrolled hypertension, or kidney disease; or BMI ≥27 plus a history of stroke, prediabetes, heart attack, or peripheral artery disease. You must be enrolled in Part D. Confirm current criteria with CMS or your plan.

Which drugs are covered?

Reported coverage includes Wegovy (injection and tablet) and Zepbound (KwikPen) for weight reduction and maintenance. Confirm the current list before your appointment, since details can change during rollout.

Does the $50 copay count toward my deductible?

No — it's outside the standard Part D benefit payment flow, so it doesn't count toward your deductible or annual out-of-pocket limit.

What happens after December 31, 2027?

Unless extended, the program ends and coverage reverts to your Part D plan's standard formulary and PA rules. Plan ahead with your prescriber and plan before that date.

Sources

📬

Practical GLP-1 guides, delivered

No miracle claims. No spam. Just helpful information for people navigating GLP-1 therapy.